AdipoPharma SAS is a biopharmaceutical / biologics company focused on novel approaches to metabolic diseases particularly Type 2 Diabetes and Cardiovascular complications. It's novel lead compound PATAS is entering human clinical trials.

The Institutes for Pharmaceutical Discovery (IPD) is a private research and consulting company headquartered in Branford, CT. Founded in 1995, IPD is the parent company to The Institute for Drug / Diabetes Discovery (IDD) and the Institute for Bioanalytics (IBA). Institutes created by IPD combine the proven experience of senior pharmaceutical executives with the scientific excellence of renowned industry researchers and consulting academic investigators.Accomplishments:• Directed strategic planning, client development, financial, operations and administrative management to all aspects of IPD, including scientific goals and objectives and intellectual property development.• Formulation of financial programs to provide funding for new and continuing operations to maximize returns on investments and to increase productivity. Successfully raised over $200 million in research support from U.S. and international pharmaceutical sponsors. • Developed strong relationships with major international universities and key investigators including Yale, Cornell, University of Pennsylvania, Georgetown, Oxford, Harvard, University of Minnesota, Baker IDI and numerous others. • Established IPD as a major drug discovery research organization with a team of over 80 scientists working on 3-4 major research programs at any given time, from target selection stage through clinical development. These programs were in Metabolic Disease, Diabetes, Diabetic Complications, Cardiovascular, Oncology, Asthma, Dermatology and Muscular Dystrophy.• Established IBA as a major provider of bioanalytical services to the pharmaceutical industry. Sponsors include Pfizer, Biorad, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Mars Inc., and Merck. • Directed specific client new product / marketing programs through IPD - Consumer Health, in the fields of Natural Products, Urology, Dermatology, Veterinary Medicine and Podiatry.

I am the Chief Executive Officer of InClinica, a global clinical contract research / consulting organization. We specialize in leading companies across all phases of preclinical and clinical development.

I serve as the Chief Executive Officer at SkinJect, Inc., a Pittsburgh-based company that has developed a novel, minimally invasive treatment for basal cell carcinoma.

I serve as Partner for Velocity Fund, a private equity fund targeting the life sciences industry. Our unique background in healthcare management and life sciences development offers a significant scientific advantage, helping to accelerate a company's trajectory.

I specialize in the life sciences industry, working with companies to form and oversee teams, identify opportunities, establish business and develop growth strategies. Currently serving as:•CEO at InClinica, a global CRO assisting pharmaceutical, biotechnology and medical device companies in the achievement of their product developmental goals.•CEO at SkinJect, a biotechnology company dedicated to combating Basal Cell Carcinoma using a proprietary drug delivery platform to deliver drugs to the top layers of the dermis.•President and CEO at E3 Therapeutics, a company focused on a novel target in inflammatory diseases.

• Assisted in development of Mars Symbioscience from its inception to its current team of more than 150 professionals.• Facilitated the launch of several new products and the development of a diverse scientific profile in all phases of the business.

I previously served as Sales Representative and Product Manager, as well as Michigan Division Manager.